Navigation Links
Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program
Date:11/2/2010

SEATTLE, Nov. 2, 2010 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has been awarded $977,917 in grants under the Therapeutic Discovery Tax Credit program that was enacted under the U.S. government's Patient Protection and Affordable Care Act. The program targets projects that show potential to produce new therapies, address unmet medical needs, reduce the long-term growth of health care costs and advance the goal of curing cancer. CTI was awarded the grants for CTI's programs pixantrone, OPAXIO, brostallicin and bisplatinates which are all focused in the area of oncology.  

"We are pleased that the U.S. Department of Health and Human Services recognizes the potential impact that CTI's research and drugs could have for patients and specifically in advancing the effort to make cancer more treatable," said James A. Bianco, M.D., CEO of Cell Therapeutics. "This program is also recognition of the importance of the contribution the biotechnology industry is making to U.S. healthcare. These grants will allow CTI to further advance its product candidates in an effort to treat areas that have significant unmet medical needs."

About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties associated with preclinical and clinical developments in the biopharmaceutical industry in general, and CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling its product candidates, that CTI cannot guarantee that its product candidates will produce new therapies, address unmet medical needs, reduce the long-term growth of health care costs or advance the goal of curing cancer, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.Media Contact:Dan Eramian T: 206.272.4343C: 206.854.1200E: deramian@ctiseattle.comwww.CellTherapeutics.com/press_roomInvestors Contact:Ed BellT: 206.282.7100Lindsey Jesch LoganT: 206.272.4347F: 206.272.4434E: invest@ctiseattle.com www.CellTherapeutics.com/investorsMedical Information Contact:T: 800.715.0944E: info@askarm.com
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
2. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
3. Shield Therapeutics Signs Agreement With AOP Orphan for ST10-021
4. Echo Therapeutics to Present at the LifeTech Capital 1st Annual Miami Medical Investors Conference
5. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
6. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
7. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
8. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
9. Cell Therapeutics Third Quarter Net Loss Decreases by 68% in 2010 Compared to 2009
10. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... Clarius Mobile Health, a digital healthcare ... this week at the American Congress of Obstetricians ... San Diego, CA from May ... perfect tool for clinicians to easily confirm pregnancy, ... pregnancy-related complications like ectopic pregnancy and placenta previa," ...
(Date:5/4/2017)... , May 4, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... ("BioLife" or the "Company"), today announced that the Company,s ... market close on Thursday, May 11, 2017, and that ... webcast at 1:30 p.m. PT that afternoon. Management will ...
(Date:5/3/2017)... , May 3, 2017  West Pharmaceutical ... innovative solutions for injectable drug administration, announced today ... Affairs and Technical Services, and Diane Paskiet ... and offering presentations focused on West,s expertise in ... products, as well as providing commentary on updated ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Myers Jackson is well known for auctioning homes ... luxury homes anywhere on the planet. The luxury home market is alive and well ... city-scapes. A quick search of “11 Spyglass Hill Auction will enlighten you on the ...
(Date:5/24/2017)... ... ... are thinking of a visit to San Francisco , fall is a great time ... visit. , Business Architecture Associates is pleased to offer 5 days of training courses, available ... package for individuals, and as 4-½ day corporate package for up to 3 employees with ...
(Date:5/24/2017)... ... May 24, 2017 , ... Technique, technique, technique – with a dash ... weights for strength training and exercise or simply lifting heavy objects, advises Dr. Kaliq ... is everything,” Dr. Chang says. “Improper technique in lifting anything heavy or an attempt ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... pharmaceutical and medical device sectors, today announced the winners of its 3rd Annual ... represent the most influential people in the healthcare industry today. , Out of ...
(Date:5/23/2017)... Newport Beach, CA (PRWEB) , ... May 23, 2017 , ... ... Capital Partners was honored to serve earlier this month as a Guest Speaker and ... by the British Royal Family and Common Purpose. , Walter Schindler ...
Breaking Medicine News(10 mins):